CN1216777A - 转人实体瘤内皮抑制因子(Endostatin)基因双歧杆菌的方法 - Google Patents
转人实体瘤内皮抑制因子(Endostatin)基因双歧杆菌的方法 Download PDFInfo
- Publication number
- CN1216777A CN1216777A CN 98111517 CN98111517A CN1216777A CN 1216777 A CN1216777 A CN 1216777A CN 98111517 CN98111517 CN 98111517 CN 98111517 A CN98111517 A CN 98111517A CN 1216777 A CN1216777 A CN 1216777A
- Authority
- CN
- China
- Prior art keywords
- bifidus bacillus
- gene
- endostatin
- solid tumor
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 108010079505 Endostatins Proteins 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 14
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 238000012546 transfer Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 59
- 239000013612 plasmid Substances 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 230000009466 transformation Effects 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 230000009465 prokaryotic expression Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 210000003038 endothelium Anatomy 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000004862 vasculogenesis Effects 0.000 claims description 3
- 241001037822 Bacillus bacterium Species 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 229940100691 oral capsule Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000008521 reorganization Effects 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 230000007998 vessel formation Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 9
- 108700008165 endostar Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002342 anti-penicillin Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101500026378 Homo sapiens Endostatin Proteins 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 98111517 CN1065911C (zh) | 1998-09-30 | 1998-09-30 | 转人实体瘤内皮抑制因子基因双歧杆菌的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 98111517 CN1065911C (zh) | 1998-09-30 | 1998-09-30 | 转人实体瘤内皮抑制因子基因双歧杆菌的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1216777A true CN1216777A (zh) | 1999-05-19 |
CN1065911C CN1065911C (zh) | 2001-05-16 |
Family
ID=5221490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 98111517 Expired - Fee Related CN1065911C (zh) | 1998-09-30 | 1998-09-30 | 转人实体瘤内皮抑制因子基因双歧杆菌的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1065911C (zh) |
-
1998
- 1998-09-30 CN CN 98111517 patent/CN1065911C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1065911C (zh) | 2001-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106190903B (zh) | 鸭疫里氏杆菌Cas9基因缺失突变株及其应用 | |
Koster et al. | Identification and characterization of the pupB gene encoding an inducible ferric‐pseudobactin receptor of Pseudomonas putida WCS358 | |
CN106282216B (zh) | 一种重组长效鸡干扰素α的制备方法 | |
JPH06505158A (ja) | 弱毒化細菌における組換えタンパク質の発現 | |
Kranz et al. | Inactivation, sequence, and lacZ fusion analysis of a regulatory locus required for repression of nitrogen fixation genes in Rhodobacter capsulatus | |
CN102199196A (zh) | 一种基因工程抗菌肽及其制备方法和应用 | |
US11970723B2 (en) | Strain producing D-allulose 3-epimerase and application thereof | |
CN101457231A (zh) | 菌影载体pmal-e-sn的构建及其在大肠杆菌中的应用 | |
CN101843899B (zh) | 耐甲氧西林金黄色葡萄球菌(mrsa)重组多亚单位基因工程疫苗及其制备方法 | |
CN109153706A (zh) | 源自乳酸菌的蛋白质及其制备方法 | |
Firth et al. | A lipoprotein signal peptide encoded by the staphylococcal conjugative plasmid pSK41 exhibits an activity resembling that of Enterococcus faecalis pheromone cAD1 | |
CN112175928B (zh) | 一种源于沙门氏菌噬菌体基因编码的蛋白在作为革兰氏阴性菌裂解酶中的应用 | |
CN101638665B (zh) | 乳酸菌单质粒Nisin诱导表达载体的构建及使用方法 | |
CN108840952A (zh) | 一种由鸡白蛋白、鸡干扰素γ和鸡干扰素α组成的融合蛋白及其制备方法 | |
CN101654681A (zh) | 一种乳酸菌食品级表达载体pMG36N及其制备方法 | |
CN112111438A (zh) | 一种印第安纳沙门氏菌菌蜕的制备方法 | |
CN1065911C (zh) | 转人实体瘤内皮抑制因子基因双歧杆菌的方法 | |
CN114989273B (zh) | 基因PlMYB1R及其在防治荔枝霜疫霉病中的应用 | |
CN109289046A (zh) | 一种具核梭杆菌FomA蛋白质疫苗以及制备方法和应用 | |
CN102241756B (zh) | 黄粉虫抗菌肽TmAMP3m在大肠杆菌中的高效表达及其应用 | |
CN101008014B (zh) | 乳酸乳球菌食品级载体 | |
CN108864300A (zh) | 鸡白蛋白-干扰素α-白介素2融合蛋白、制备方法及其编码基因、一种鸡长效干扰素 | |
CN105732792A (zh) | 一种酵母表达的鸡Cathelicidin1抗菌肽及其制备方法与应用 | |
NL8020132A (nl) | Een vaccin voor de bestrijding van pleuropneumonie bij varkens en een werkwijze en een substraat voor de aerobe fermentatie van haemophilus pleuropneumoniae. | |
CN110352961A (zh) | 一种经基因工程改造的大肠杆菌菌株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INNER MONGOLIA PUZE BIOLOGICAL PRODUCTS CO., LTD. Free format text: FORMER OWNER: XU GENXING Effective date: 20131212 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210049 NANJING, JIANGSU PROVINCE TO: 010000 HOHHOT, INNER MONGOLIA AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131212 Address after: 010000 the Inner Mongolia Autonomous Region Hohhot Jinchuan Development Zone Industrial Park Gold seven road Patentee after: Neimenggu Puze Biological Product Co., Ltd. Address before: Nanjing City, Jiangsu province 210049 horses Street No. 2 box 4901 Department Patentee before: Xu Genxing |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010516 Termination date: 20170930 |